TherapeuticsMD (NSDQ:TXMD) has submitted its bio-identical hormone therapy to the FDA for approval as a treatment for moderate-to-severe vasomotor symptoms due to menopause.
The company’s investigational combination of estradiol and progesterone is delivered in a single, oral soft-gel capsule.
Get the full story at our sister site, Drug Delivery Business News.
The post TherapeuticsMD submits NDA for hormone therapy to treat vasomotor symptoms appeared first on MassDevice.